ETC
CYTK icon

Exchange Traded Concepts’s Cytokinetics CYTK Stock Holding History

Exchange Traded Concepts’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-128
Closed -$6.02K – 1302
2024
Q4 		$6.02K Sell
128
-32
-20% -$1.66K ﹤0.01% 1361
2024
Q3 		$8.45K Buy
+160
New +$8.92K ﹤0.01% 1294
2024
Q2 		– Sell
-55
Closed -$3.86K – 1237
2024
Q1 		$3.86K Buy
+55
New +$4.25K ﹤0.01% 1206

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Exchange Traded Concepts's CYTK Position: Q1 2025 in Review

Exchange Traded Concepts sold out of Cytokinetics (CYTK) in Q1 2025, closing a stake of 128 shares — an estimated $6.02K sold.

Exchange Traded Concepts first reported a position in CYTK in Q1 2024 and held it in 3 quarters. The position peaked at $8.45K in Q3 2024. 355 funds tracked by Wall St. Rank hold CYTK as of Q1 2025.

  • Exchange Traded Concepts reported no remaining Cytokinetics position as of Q1 2025 after selling out during the quarter.
  • Exchange Traded Concepts sold 128 Cytokinetics shares in Q1 2025, an estimated $6.02K.
  • Exchange Traded Concepts first reported a position in Cytokinetics in Q1 2024 and held it in 3 quarters.
  • Exchange Traded Concepts's Cytokinetics position peaked at $8.45K in Q3 2024.
  • 355 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2025.

Based on Exchange Traded Concepts's 13F filing for Q1 2025, filed 17 Apr 2025.